Comparing the current results to its competitors, Sanofi reported Revenue increase in the 4 quarter 2025 by 5.49 % year on year. The revenue growth was below Sanofi's competitors' average revenue growth of 11.57 %, achieved in the same quarter.
Sanofi's Comment on Competition and Industry Peers
Sanofi faces challenges to its patent protections and regulatory exclusivities for its pharmaceutical products. Despite unexpired patents, generic versions of products such as Allegra in the US and Multaq in the EU have been launched by competitors. These competitors may circumvent patents by developing different formulations, salt or crystalline forms, or indications not covered by Sanofi's patents. In the US, generic competitors can challenge patents by filing Abbreviated New Drug Applications (ANDAs) or under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act. Regulatory exclusivity periods, including the FDA's five-year exclusivity for New Chemical Entities and 12-year exclusivity for biological drugs, provide additional protection independent of patents. Sanofi is engaged in ongoing patent litigation to defend its intellectual property rights.
Immunitybio Inc operates on a business model that focuses on developing and commercializing innovative immunotherapies and vaccines to address various diseases and medical conditions. They aim to use their broad scientific expertise, technology platforms, and strategic partnerships to advance their products and improve patient outcomes in healthcare.
Journey Medical Corporation is a pharmaceutical and medical device company that specializes in developing and commercializing innovative products for dermatology and aesthetics. Their business model revolves around conducting research and development to create new products, acquiring the necessary regulatory approvals, and partnering with healthcare professionals to effectively distribute and market these products. By focusing on dermatology and aesthetics, Journey Medical Corporation aims to address unmet medical needs and provide cutting-edge solutions to improve patient outcomes in these fields.
Connect Biopharma Holdings Limited is a biotechnology company that develops novel therapies for inflammatory diseases by targeting the immune system. Their business model includes research and development of innovative drugs, clinical trials, and partnerships with pharmaceutical companies for commercialization.
Sources:
Sanofi’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Sanofi versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
